Published in Vaccine Weekly, September 14th, 2005
The consolidated financial statement, compiled with IFRS, shows Mologen to have had a business volume of EUR.4 million (US$.49 million) in the first half of 2005. The volume is expected to increase significantly in the second half year, due to the revenues anticipated from cell- and gene-therapy centers. In the first half of 2004, the business volume was EUR1.1 million (US$1.35 million).
The operational cash flow was EUR-1.7 million (US.-$2.09 million) during the first half of 2005 due to increased activities in research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly